Nifedipine Release From Extended-Release Solid Oral Formulations Using In Vitro Dissolution Testing Under Simulated Gastrointestinal Compression.
Controlled/extended release
Dissolution testing
Gastrointestinal compression
In vitro model(s)
Solid oral formulation
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
24
02
2020
revised:
20
03
2020
accepted:
23
03
2020
pubmed:
3
4
2020
medline:
22
6
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
Drug release plays a critical role in defining bioavailability for an extended release solid oral drug products and predictive dissolution tests are desired to establish clinically relevant quality standards for batch release. The objective of this study focuses on exploring the possible impacts of 1 gastrointestinal (GI) parameter for 1 drug: simulated GI contractions on nifedipine release (in 2 extended release solid oral formulations). The 60 mg nifedipine osmotic pump product A, and polymer matrix-based products B and C were examined in the study. An in-house dissolution system was used to simulate various levels of GI contractions on tested samples, and to monitor changes of sample mechanical properties during dissolution testing. The results show that the polymer matrix-based formulation failed to provide controlled release when simulated GI contraction was above 100 g of force. The method may be useful for polymer matrix-based products to assess potential formulation-related interactions with the GI tract during in vivo drug dissolution.
Identifiants
pubmed: 32240693
pii: S0022-3549(20)30182-9
doi: 10.1016/j.xphs.2020.03.023
pii:
doi:
Substances chimiques
Delayed-Action Preparations
0
Nifedipine
I9ZF7L6G2L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2173-2179Informations de copyright
Published by Elsevier Inc.